Oman – Women’s health is being transformed and further prioritized with the launch of Organon (NYSE: OGN), the only global company of its size focused on women’s health. With the aim of improving the standard of living for women in Oman and supporting the future of healthcare, Organon goes beyond traditional focus areas of women health and deliver impactful medicines & solutions based on unique patient needs.

Managing Director Ramy Koussa of MENAT (Middle East, North Africa, and Turkey) in Organon, highlights the vision of the company, “As the MENAT region continues to grow and is expected to expand further in the coming years, we recognize the need to focus on women-specific health conditions and treatments that impact the everyday life of women. This launch will not only transform women’s healthcare, but will also create over 400 job opportunities across MENAT. With our expertise, products, and technology in women-related conditions, we want to influence change in the region and empower women to take charge of their health to live better lives.”  

The Organon executive leadership team rang the opening bell at the New York Stock Exchange (NYSE) to mark the first day of active trading. Recognizing the need to listen to and act on women’s experiences to address the challenges in women’s health, Organon gathered voices from around the world to create the “Wall of Voices,” a multimedia installation outside of the NYSE sharing powerful perspectives, voices and images. Dr. Hanan Abdullah Al Mahrooqi, Senior Consultant Family Physician and Head of Bausher Specialized Polyclinic said, “Women are the spinal cord of the family and the primary caregiver to all members, giving good care to her is giving the care to the whole community”. Women everywhere are invited to take the “microphone” to add their voice to the digital “Wall of Voices” at www.HereForHerHealth.com.       

Organon Oman’s Lead, Razan Gharaibeh said “A unique offering that we are bringing to Oman to best cater to the unique needs of women includes biosimilars. In line with our commitment to increase medical accessibility to women, biosimilars play a crucial role in reducing cost pressure on the healthcare system and provide more access to biologic therapies. We will always be here for her health for a healthier woman, every day.”

The three core pillars that lead Organon’s offerings in Oman include:

  • Biosimilars: Actively building a strong foundation by broadening the reach of offerings into new geographies while expanding through new collaborations and into new disease areas.
  • Women’s Health: With more than 140 therapies that are being investigated by multiple companies across the women’s health industry, our goal is to add value by identifying and advancing the most promising opportunities for women.
  • Established Brands: Our portfolio of over 60 medicines span several areas including cardiovascular disease, respiratory conditions, non-opioid pain management and dermatology. This diverse set of products and trusted brands are critical drivers of Organon’s growth that will enable us to invest in new opportunities.

Organon has an international footprint that serves people in more than 140 markets, with nearly 80% of its approximately $6.5 billion in annual revenue generated outside the U.S. Organon believes it is well positioned for organic low-to-mid-single digit growth from its 2021 base of business. Their approach to innovation is led by patient needs and the use of extensive global capabilities in clinical development and patient safety with the greatest potential to impact women’s health. Sandy Milligan, Head of Organon Research & Development stated “Women have been told to accept and normalize their conditions as a part of like, Organon’s mission is to change this. We believe this approach will be very successful — we hope to discover the ability to identify diseases earlier, the ability to modify the course of diseases or healthcare conditions and to ultimately, improve the quality of life for women at all stages.”

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit www.organon.com  and connect with us on LinkedIn, Facebook, and Instagram.

Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.